Patents Assigned to Regeneron Pharmaceuticals, Inc.
-
Publication number: 20250143922Abstract: Disclosed are devices and methods for facilitating directed delivery of a medicament into a human organ of a patient. An apparatus to facilitate directed delivery of a medicament into a human organ of a patient may include a container configured to enclose the medicament, a needle having a passage therethrough and a sharp distalmost tip, and a needle guard at least partially surrounding a shaft of the needle. The needle guard may include a distal surface, wherein the sharp distalmost tip of the needle may be configured to extend through an opening in the distal surface. The needle guard may be moveable relative to the needle along an axis of the needle to control a distance from the distal surface to the distalmost tip of the needle.Type: ApplicationFiled: November 8, 2024Publication date: May 8, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Jessica MASTROPIETRO, Andrew DUMONT, Bryan GRYGUS, Sarah ELLIS, Parker VALDEZ, Trevor LANGLEY, Sindhuja KUCHIBHATLA, Igor DROBNJAK, Danielle LAIACONA, Daniel HALBIG, Eric HOLOWKA, Bibiana IGLESIAS, Carmelo ROMANO
-
Patent number: 12291563Abstract: Improved methods for large scale production of proteins and/or polypeptides in cell culture is provided. In accordance with the present invention, the method provides for culturing cells that have metabolically shifted. The use of such a method or system allows high levels of protein or polypeptide production and reduces accumulation of unwanted metabolic waste such as lactate. Proteins and polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, immunogenic, or other commercial biologic compositions, such as antibodies.Type: GrantFiled: June 17, 2022Date of Patent: May 6, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Shawn Lawrence, Michelle Lafond, Ann Kim, Amy S. Johnson, Brandon Veres, Mark Czeterko, Kristen Whalen
-
Patent number: 12291571Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.Type: GrantFiled: July 13, 2022Date of Patent: May 6, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Ana Kostic, Ludmila Kelly, Xia Liu, Brendan J. Classon, Allen Radin
-
Patent number: 12291559Abstract: Disclosed are compositions and methods for targeted treatment of cancer. The present disclosure provides chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors are specific for a low density cancer antigen or peptide in groove antigen.Type: GrantFiled: October 20, 2023Date of Patent: May 6, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David DiLillo, Thomas Craig Meagher
-
Patent number: 12291560Abstract: The present disclosure provides improved compositions for adoptive T cell therapies targeting CD33 for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting CD33 and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: GrantFiled: December 13, 2019Date of Patent: May 6, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Jordan Jarjour, Wai-Hang Leung
-
Patent number: 12286677Abstract: The disclosure provides methods of identifying a human subject as a candidate for treating or inhibiting a liver disease by inhibiting HSD17B13. The disclosure also provides methods of treating a subject who is PNPLA3 Ile148Met+ by administering an inhibitor of HSD17B13. The disclosure also provides method of detecting a PNPLA3 Ile148Met variant and functional HSD17B13 in a subject. The disclosure also provides method of identifying a subject having a protective effect against liver disease. The disclosure also provides inhibitors of HSD17B13 for use in the treatment of a liver disease.Type: GrantFiled: May 30, 2023Date of Patent: April 29, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Yurong Xin, Jesper Gromada, Xiping Cheng, Frederick Dewey, Tanya Teslovich Dostal, Claudia Schurmann, Aris Baras, Noura Abul-Husn
-
Publication number: 20250127992Abstract: Disclosed herein are delivery devices for delivering a volume of a drug product, placebo product, or other product including a fluid. The devices may include a barrel having a longitudinal axis, a proximal end region, and a distal end region. The proximal end region may include an opening, and the barrel may be configured to receive a drug therein. A plunger rod may be disposed at least partially inside the barrel and protruding from the opening. The plunger rod may include a rack having a plurality of teeth. The device may further include a pinion having a plurality of teeth configured to engage with the plurality of teeth of the rack, and rotation of the pinion against the rack may move at least a part of the plunger rod along the longitudinal axis of the barrel.Type: ApplicationFiled: December 24, 2024Publication date: April 24, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Sibgat ULLA, Danielle LAIACONA, Ross KENYON, Trevor LANGLEY, Bryan GRYGUS, Eric HOUDE, Jeremy McNAMARA, Kathryn VENUTO
-
Publication number: 20250129363Abstract: Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.Type: ApplicationFiled: December 17, 2024Publication date: April 24, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Marine Prissette, Matthew Koss, Wen Fury, Brian Zambrowicz
-
Patent number: 12280124Abstract: Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for targeting glucagon-like peptide 1 receptor (GLP1R). In certain embodiments, provided are peptidomimetic payloads and linker-payloads and methods of making same. More specifically, GLP1 peptidomimetics, antibody-drug conjugates, and compositions which comprise anti-GLP1R antibodies and GLP1 peptidomimetic payloads and methods of treating GLP1R-associated conditions are provided.Type: GrantFiled: September 14, 2021Date of Patent: April 22, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Amy Han, Haruka Okamoto, William Olson
-
Patent number: 12281173Abstract: The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3).Type: GrantFiled: March 3, 2020Date of Patent: April 22, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy
-
Patent number: 12282004Abstract: A modular test fixture is configured to quickly support test samples of different configurations for testing.Type: GrantFiled: September 16, 2020Date of Patent: April 22, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Christopher Hunter, Ruchika Sharma, Wesley Mahunik
-
Patent number: 12274747Abstract: The present invention provides compositions and methods for treating cancer and inhibiting cytokine release syndrome (CRS). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a CD40 antagonist or a CAR-T cell expressing a CD40 antagonist in combination with a therapeutically effective amount of a CD3 multispecific antigen binding molecule.Type: GrantFiled: January 28, 2022Date of Patent: April 15, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Kara Olson, Olga Sineshchekova, Eric Smith, Chia-Yang Lin
-
Patent number: 12274865Abstract: Disclosed herein are devices and methods for delivering a predetermined volume of a drug substance or other product including a fluid. An exemplary device may include a body configured to receive a drug substance therein, and a plunger rod disposed at least partially inside the body to distally move a stopper in the body. The device may include a component configured to regulate distal movement of the plunger rod in a priming step and in a subsequent delivery step, so that the device may be accurately primed and may accurately dispense a predetermined volume of a drug substance.Type: GrantFiled: August 1, 2022Date of Patent: April 15, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Trevor Langley, Justin Bechstein, Jeremy Odegard, Sibgat Ulla, Daniel Halbig, Bryan Grygus, Prithvi Singh, Andrew Dumont, David Nett, Tasha Gillum, Ryan Ainsworth
-
Patent number: 12275792Abstract: The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin.Type: GrantFiled: November 30, 2021Date of Patent: April 15, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jesper Gromada, Panayiotis Stevis, Judith Altarejos
-
Patent number: 12268730Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.Type: GrantFiled: October 27, 2023Date of Patent: April 8, 2025Assignee: Regeneron Pharmaceuticals, Inc.Inventor: George D. Yancopoulos
-
Patent number: 12269897Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.Type: GrantFiled: April 5, 2023Date of Patent: April 8, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald
-
Patent number: 12269889Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.Type: GrantFiled: October 11, 2022Date of Patent: April 8, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
-
Publication number: 20250109194Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: ApplicationFiled: December 11, 2024Publication date: April 3, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Tong ZHANG, Samuel DAVIS, Chia-Yang LIN, Eric SMITH, Erica PYLES, Michael ROSCONI, Nina LIU, Supriya PATEL, Andrew J. MURPHY
-
Publication number: 20250109207Abstract: The present disclosure relates to chimeric heavy chain constant domains having reduced effector function. Also disclosed are recombinant polypeptides comprising such chimeric heavy chain constant domains, including antibodies such as multispecific antibodies, fusion proteins, and other recombinant proteins. Nucleic acids encoding such recombinant polypeptides are also disclosed, as well as cells expressing such recombinant polypeptides and pharmaceutical compositions comprising such recombinant polypeptides.Type: ApplicationFiled: April 20, 2023Publication date: April 3, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Naga Suhasini AVVARU, Samuel DAVIS, Chia-Yang LIN, Yang SHEN
-
Publication number: 20250108173Abstract: A drug delivery device is disclosed, wherein the device comprises a housing; a cap located at a proximal end of the housing, the cap including a first pair of deflectable arms and a second pair of deflectable arms; a product vessel arranged in the housing, and a needle coupled to a distal end of the product vessel; a plunger rod for dispensing a product from the product vessel, wherein the plunger rod is slidably received within the cap and partially disposed inside the product vessel; and a needle cover at least partially disposed in the housing, wherein the first pair of deflectable arms are configured to deflect radially inwards towards the plunger rod and the second pair of deflectable arms are configured to radially outwards away from the plunger rod.Type: ApplicationFiled: October 1, 2024Publication date: April 3, 2025Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Trevor LANGLEY, Bryan C. GRYGUS, Danielle Laiacona, Noah Bennett, Alexander Roumanidakis, Jessica Miklinski, Maya Vanderhorst, Parker Valdez